Gobivaz Biosimilar Earns EEA Approval, Expanding Access to Anti-TNF Therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
Dateline – November 17 2025 | Minneapolis & Miami PetVivo Holdings, Inc. announced that its exclusive AI-technology partner, Digital...
